Guillain-Barré syndrome

Seneviratne, Udaya

doi:10.1136/pmj.76.902.774

Cited by 71 publications

(26 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ho TW, et al in Western China study 11 show AIDP -19%, AMAN 65%, AMASAN 10-15%. Udaya Senevaratne, Srilanka Study (2000) 12 shows, 76% AIDP, 24% AMAN and 10% comprises other subtype of GBS which was comparable to our study. Rong KL, et al (1997) 13 Taiwan study showed AIDP (49%), AMAN (4%), MFS (18%) and others 29%.…”

Section: Discussionsupporting

confidence: 81%

“…In Emilia Romagna study in Italy (1999) 14 65% cases had associated infection (59% fever, 18.2% diarrhea); Cheng Q, et al Sweden study (2000) 18 shows 60% respiratory tract illness, 28% diarrhea, 45% RTI. Paul H, et al (2001) 19 study show 71% associated illness, Udaya Seneviratne, Srilanka study (2000) 12 show 60% associated illness (20% Diarrhea, 40% Respiratory tract infection), Nicholas DL, et al 20 study shows 71% associated illness, Taiwan study (1997) show 67% associated illness (54% respiratory infection). Jacob BC,et al Netherlands study (1998) 21 show 32% diarrhea and 19% respiratory tract illness.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Guillain Barre Syndrome: Major Cause of Acute Flaccid Paralysis in Children and Adolescents of Nepal

Sharma

Singh

Shah

2011

J. Nepal Paedtr. Soc.

View full text Add to dashboard Cite

Introduction. Guillain Barre Syndrome (GBS) is a post infectious polyneuropathy involving mainly motor but sometimes sensory and autonomic nerves. It is an acquired disease of the peripheral nerves that is characterized by rapidly progressing paralysis, areflexia and albumino-cytological dissociation in CSF. Methodology: Prospective, descriptive, observational, hospital based study was carried out to find out the clinico-epidemiological features of GBS including existing treatment modalities and its outcome. All cases fulfilled the criteria for AFP (Acute flaccid Paralysis) surveillance was included. Cases were reviewed for full medical history and examinations. To confirm the diagnosis, necessary investigations were carried out and combined with clinical symptoms. Results: Thirty patients were included in the study during study period. Among them 90% were diagnosed as GBS, 7.4% patients of GBS were associated with hypokalemic paralysis, 7.4% diagnosed as transverse myelitis and 3.7% diagnosed as idiopathic neuropathy. Different types of GBS were classified as AIDP (Acute inflammatory demyelinating polyneuropathy) 62.96%, AMAN (Acute motor axonal neuropathy) -25.52%, AMASAN (Acute motor and sensory axonal neuropathy) -3.3% and MFS (Miller fisher's syndrome) -6.6% according to NCV result. Male female ratio is 1.7:1.0. There was 14.8% patients had relapse within 5 year. Associated diseases were URTI, pneumonia, sore throat and diarrhea. Facial Nerve palsy was commonest cranial nerve involvement.Sixty percentage of patients presented with sensory symptoms. There was transient bowel and bladder involvement in 20% of the cases. 69.2% patients became bed ridden at the nadir. There was albumin-cytological dissociation in 80% case. Majority of patients improved with supportive treatment alone, 19.5% patient required ventilator support among them 40% died. 7.4% of cases expired during treatment. Half of the patients fully recovered within 3 months. Conclusion: GBS is the commonest cause of AFP, AIDP being commonest subtype in our setting. We have to improve our existing treatment facilities and extend to different centers to detect and treat GBS. Most of the patients improve with supportive treatment alone. Ventilator support indicates grave prognosis.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Guillain Barre Syndrome: Major Cause of Acute Flaccid Paralysis in Children and Adolescents of Nepal

Sharma

Singh

Shah

2011

J. Nepal Paedtr. Soc.

View full text Add to dashboard Cite

show abstract

“…It is important to distinguish RGBS from two clinical entities; (1) GBS with treatment related fluctuations (GBS-TRF), (2) Chronic inflammatory demyelinating polyneuropathy (CIDP). Since our patient had a long asymptomatic period, GBS-TRF is less likely but CIDP comes as a differential diagnosis.…”

Section: Investigationsmentioning

confidence: 99%

“…This results in marked inflammation of the peripheral nerves, resulting in demyelination and defective impulse propagation. It is a heterogeneous group of disorders which involves motor, sensory and autonomic nervous systems to varying degrees depending on the sub type; [1] Acute inflammatory demyelinating polyneuropathy, [2] Acute motor axonal neuropathy, [3] Acute motor sensory axonal neuropathy, [4] Miller Fisher syndrome, [5] Acute pan-autonomic neuropathy and [6] Pure sensory GBS.…”

Section: Investigationsmentioning

confidence: 99%

A case of a recurrent GBS

Morshed

Rahman

Reza

et al. 2017

Bangladesh Crit Care J

View full text Add to dashboard Cite

Background: Guillain-Barré syndrome is an acquired polyradiculo-neuropathy, often preceded by an antecedent event. It is a monophasic disease but a recurrence rate of 16 % is documented in a subset group of patients.Case presentation: Thirty-five-years-old female with past history of near complete recovery following Guillain-Barré syndrome 17 years back presented with acute, ascending symmetrical flaccid quadriparasis extending to bulbar muscles and respiratory compromise needing mechanical ventilation. Nerve conduction study revealed AMAN variant of Guillain-Barré syndrome. Cerebrospinal fluid analysis done after 1 weeks during recurrent episode revealed albuminocytologic dissociation. She was treated with intravenous immunoglobulin resulting in a remarkable recovery.Conclusion: Recurrence of Guillain-Barré syndrome can occur in a subset of patients with Guillain-Barré syndrome even after many years of asymptomatic period. Most patients with recurrent GBS respond favourably to treatment with plasmapheresis or IVIG.Bangladesh Crit Care J September 2017; 5(2): 135-138

show abstract

“…[1][2][3][4] However, severe neurological complications involving the peripheral nervous system (PNS) are relatively rare, occurring in less than 3% of transplanted patients and presents with acute or chronic inflammatory demyelinating polyneuropathy. 2,[4][5][6][7][8] An alternative approach for allogeneic SCT, aimed at attenuating treatment-related toxicity by reducing the conditioning chemotherapy dose and increasing the cure rate by inducing a graft-versus-tumour effect, has recently been introduced in patients with haematological malignancies. [9][10][11][12] We describe the incidence, characteristics and outcome of neurological complication following alemtuzumab-based reduced-intensity SCT (RISCT), emphasizing the relatively high incidence of PNS involvement observed in these patients.…”

mentioning

confidence: 99%

Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation

Avivi

Chakrabarti

Kottaridis

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:We report the incidence, characteristics and outcome of neurological complications occurring following reducedintensity conditioning (RIC) in 85 patients who received a related/unrelated donor stem cell transplantation following therapy with alemtuzumab, fludarabine and melphalan. Six patients (probability 8.9%) developed severe neurological complications at a median of 151 days (24-334 days). Five of them presented with progressive peripheral sensori-motor radiculo-neuropathy and/or myelitis, preceded by one or more viral reactivation/ infection. Despite treatment with immunoglobulins/ plasmapheresis/steroids, four died of respiratory failure due to progressive peripheral neurophathy. Viral infection was identified as the only risk factor for the development of neurological complications. Patients who are treated with alemtuzumab-based RIC may have a lower risk of developing regimen-related neurological complications, but are more susceptible to develop peripheral radiculoneuropathy or myelitis. This phenomenon may be possibly related to viral infection associated with delayed immunological recovery or immunological dysregulation caused by alemtuzumab-induced T-cell depletion. Almost one quarter of the patients who undergo a conventional allogeneic stem cell transplant (SCT) may develop neurological complications within the first year after transplantation, related to drug toxicity, central nervous system (CNS) hemorrhage or infections. 1-4 However, severe neurological complications involving the peripheral nervous system (PNS) are relatively rare, occurring in less than 3% of transplanted patients and presents with acute or chronic inflammatory demyelinating polyneuropathy. 2,[4][5][6][7][8] An alternative approach for allogeneic SCT, aimed at attenuating treatment-related toxicity by reducing the conditioning chemotherapy dose and increasing the cure rate by inducing a graft-versus-tumour effect, has recently been introduced in patients with haematological malignancies. [9][10][11][12] We describe the incidence, characteristics and outcome of neurological complication following alemtuzumab-based reduced-intensity SCT (RISCT), emphasizing the relatively high incidence of PNS involvement observed in these patients. Patients and methods PatientsIn total, 85 patients underwent nonmyeloablative conditioning in two major collaborating centres between June 1997 and October 2001. The eligibility criteria for receiving reduced-intensity conditioning have been previously described and local ethics committee of the participating centres approved the study design. 10,13 Conditioning regimen and GVHD prophylactic therapy. Conditioning treatment consisted of alemtuzumab (IgG1 humanized monoclonal antibody against CD52) 20 mg/day on days À8 to À4; fludarabine 30 mg/m 2 from days À7 to À3 and melphalan 140 mg/m 2 on day À2. Cyclosporine A (CSA), 3 mg/kg/day was started from day À1 as GVHD prophylaxis, with a targeted level of 200-300 ng/ml for the first 2-3 months, and then tapered down over next 2-3 months. CSA was ...

show abstract

Guillain-Barré syndrome

Cited by 71 publications

References 111 publications

Guillain Barre Syndrome: Major Cause of Acute Flaccid Paralysis in Children and Adolescents of Nepal

Guillain Barre Syndrome: Major Cause of Acute Flaccid Paralysis in Children and Adolescents of Nepal

A case of a recurrent GBS

Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation

Contact Info

Product

Resources

About